VANCOUVER, Feb. 3, 2017 /CNW/ - RepliCel Life Sciences
Inc. (OTCQB: REPCF) (TSXV: RP) ("RepliCel" or the "Company") is
pleased to announce the appointment of Hugh
Rogers, to its Board of Directors. Mr. Rogers holds a
B.Sc. degree from the University of British
Columbia and a Legum Baccalaureus (LLB) degree from
University of New Brunswick. He is a
member in good standing of the law society of British Columbia.
Mr. Rogers has extensive corporate finance and restructuring
experience through his work with various TSX-V listed issuers and
private companies including his most recent roles as Chief
Executive Officer of Coronado Resources Ltd. since March 2015 and Vice President Corporate Finance
at 3D Signatures Inc. since April
2015. His corporate finance, restructuring and regulatory
experience has been primarily focused on start-ups and small cap
companies in the resource and biotechnology industries. Mr. Rogers
also serves as a Director of Kootenay Zinc Corp. and Coronado
Resources Ltd.
RepliCel's Chairman and former CEO, David M. Hall commented, "We are fortunate to
have someone of Hugh's caliber, work ethic and track record of
success, join the team. His biotechnology and financing knowledge
combined with his network will undoubtedly help us steer the
Company forward in achieving its corporate and fiscal goals."
"It's an exciting time to join RepliCel," stated Mr. Rogers.
"With data on multiple trials expected early this year and a
recently streamlined capital structure, RepliCel has started off
2017 in a very attractive position. I look forward to working with
the Company and building value for shareholders."
"Hugh's addition to the Board is another step forward in the
Company's transformation that we began in 2016," stated RepliCel's
President and Chief Executive Officer, R.
Lee Buckler. "RepliCel is poised for an exciting year
building on our existing momentum and near-term milestones."
The Company has granted stock options to Hugh Rogers Inc. for
the purchase of up to 75,000 common shares of the Company pursuant
to its Stock Option Plan. Each option is exercisable for a
period of five years at a price of $1.64 per common share.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on
developing autologous cell therapies that address conditions caused
by a deficit of healthy cells required for normal tissue healing
and function. The Company's product pipeline is comprised of two
ongoing clinical trials (RCT-01 for tendon repair and RCS-01 for
skin rejuvenation) as well as its RCH-01 hair restoration product
under exclusive license by Shiseido Company for certain Asian
countries.
All product candidates are based on RepliCel's innovative
technology, utilizing cell populations isolated from a patient's
healthy hair follicles. RepliCel has also developed a proprietary
injection device (RCI-02) optimized for the administration of its
products and licensable for use with other dermatology
applications. Please visit http://replicel.com/ for additional
information.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
SOURCE RepliCel Life Sciences Inc.